26 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Development of Potent and Selective Antagonists for the UTP-Activated P2Y
University of Bonn
4-Alkyloxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety.
Bar-Ilan University
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.
University of Bonn
Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold.
University of Bonn
Identification of hydrolytically stable and selective P2Y(1) receptor agonists.
Bar-Ilan University
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
University of Bonn
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.
Niddk
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists.
University of Bonn
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP.
Ucb-Group
Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
University of Bonn
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.
National Institute of Diabetes and Digestive and Kidney Diseases
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.
National Institute of Diabetes
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.
Inspire Pharmaceuticals
Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues.
Bar-Ilan University
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphated-ester modifications as selective agonists of the P2Y(4) receptor.
Niddk
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.
University of Bonn
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
National Institute of Diabetes and Digestive and Kidney Diseases
Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.
University of Nottingham
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.
National Institute of Diabetes and Digestive and Kidney Diseases